Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images

PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer

(2020) Xiaodong Wu et al.   EJNMMI Research

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

(2020) Bingxi He et al.   Journal for ImmunoTherapy of Cancer

Non-invasive decision support for NSCLC treatment using PET/CT radiomics

(2020) Wei Mu et al.   Nature Communications

Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer

(2019) Ruohua Chen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report

(2019) Ilke Tunali et al.   LUNG CANCER

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

(2019) S Trebeschi et al.   ANNALS OF ONCOLOGY

Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result

(2019) Mengmeng Jiang et al.   ACADEMIC RADIOLOGY

18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer

(2019) Mario Jreige et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

(2019) Laura Fancello et al.   Journal for ImmunoTherapy of Cancer

Hypoxia and acidosis: immune suppressors and therapeutic targets

(2018) Sultan Damgaci et al.   IMMUNOLOGY

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

(2018) Ming Sound Tsao et al.   Journal of Thoracic Oncology

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlation of radiomic features with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC) to predict recurrence and overall survival (OS).

(2018) Pradnya Dinkar Patil et al.   JOURNAL OF CLINICAL ONCOLOGY

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

(2018) Roger Sun et al.   LANCET ONCOLOGY

Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors

(2017) Sabrina Rossi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma

(2017) Deepa Rangachari et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma

(2017) Kazuki Takada et al.   LUNG CANCER

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Limb proportions show developmental plasticity in response to embryo movement

(2017) A. S. Pollard et al.   Scientific Reports

Defining the biological basis of radiomic phenotypes in lung cancer

(2017) Patrick Grossmann et al.   eLife

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery

(2016) Egesta Lopci et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

PD-L1 Expression in Lung Cancer

(2016) Hui Yu et al.   Journal of Thoracic Oncology

CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma

(2016) Ying Liu et al.   RADIOLOGY

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

cocor: A Comprehensive Solution for the Statistical Comparison of Correlations

(2015) Birk Diedenhofen et al.   PLoS One

PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients

(2014) Shenyou Sun et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Hypoxia-Inducible Factors in Physiology and Medicine

(2012) Gregg L. Semenza   CELL

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER